Nature Communications (Nov 2020)
Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys
- Shuang Wang,
- Yun Peng,
- Rongjuan Wang,
- Shasha Jiao,
- Min Wang,
- Weijin Huang,
- Chao Shan,
- Wen Jiang,
- Zepeng Li,
- Chunying Gu,
- Ben Chen,
- Xue Hu,
- Yanfeng Yao,
- Juan Min,
- Huajun Zhang,
- Ying Chen,
- Ge Gao,
- Peipei Tang,
- Gang Li,
- An Wang,
- Lan Wang,
- Jinchao Zhang,
- Shuo Chen,
- Xun Gui,
- Zhiming Yuan,
- Datao Liu
Affiliations
- Shuang Wang
- Mabwell (Shanghai) Bioscience Co., Ltd
- Yun Peng
- Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences
- Rongjuan Wang
- Mabwell (Shanghai) Bioscience Co., Ltd
- Shasha Jiao
- Mabwell (Shanghai) Bioscience Co., Ltd
- Min Wang
- Mabwell (Shanghai) Bioscience Co., Ltd
- Weijin Huang
- Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control
- Chao Shan
- State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences
- Wen Jiang
- Mabwell (Shanghai) Bioscience Co., Ltd
- Zepeng Li
- Mabwell (Shanghai) Bioscience Co., Ltd
- Chunying Gu
- Mabwell (Shanghai) Bioscience Co., Ltd
- Ben Chen
- Mabwell (Shanghai) Bioscience Co., Ltd
- Xue Hu
- State Key Laboratory of Virology, Wuhan Institute of Virology, Chinese Academy of Sciences
- Yanfeng Yao
- Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences
- Juan Min
- Wuhan Institute of Virology, Chinese Academy of Sciences
- Huajun Zhang
- Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences
- Ying Chen
- Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences
- Ge Gao
- Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences
- Peipei Tang
- Mabwell (Shanghai) Bioscience Co., Ltd
- Gang Li
- Mabwell (Shanghai) Bioscience Co., Ltd
- An Wang
- Mabwell (Shanghai) Bioscience Co., Ltd
- Lan Wang
- Key Laboratory of the Ministry of Health for Research on Quality and Standardization of Biotech Products, National Institutes for Food and Drug Control
- Jinchao Zhang
- Mabwell (Shanghai) Bioscience Co., Ltd
- Shuo Chen
- Ludwig Cancer Research, Nuffield Department of Medicine, University of Oxford
- Xun Gui
- Mabwell (Shanghai) Bioscience Co., Ltd
- Zhiming Yuan
- Center for Biosafety Mega-Science, Wuhan Institute of Virology, Chinese Academy of Sciences
- Datao Liu
- Mabwell (Shanghai) Bioscience Co., Ltd
- DOI
- https://doi.org/10.1038/s41467-020-19568-1
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 8
Abstract
Here the authors characterize a monoclonal antibody from a COVID-19 convalescent patient that interferes with SARS-CoV-2 spike binding to ACE2 and has prophylactic and therapeutic activity in non-human primates. Antibody-dependent enhancement of infection is prevented by mutating the Fc region of the antibody.
